CooperCompanies Stock Rises After 2Q Rev Increases, Topping Analyst Estimates

Dow Jones

Jun 05

By Kelly Cloonan

Shares of CooperCompanies gained after the company logged higher sales in its latest quarter that topped Wall Street's estimates.

The stock rose 4.8% to $65.01 in after-hours trading on Thursday. Through market close, shares were down 24% year to date.

The medical device company said revenue rose 8% to $1.08 billion in the second quarter, topping analyst estimates of $1.05 billion, according to FactSet.

Chief Executive Al White said the results were supported by new product launches and favorable demand drivers.

CooperCompanies also posted a second-quarter loss of $77.9 million, or 40 cents a share, compared with a profit of $87.7 million, or 44 cents a share, a year earlier. The loss was driven by a litigation-related charge to resolve outstanding claims associated with a 2023 voluntary product recall at CooperSurgical, the company said.

Adjusted earnings per share were $1.21, above FactSet analyst estimates of $1.10 a share.

For the full year, the company now expects revenue of $4.29 billion to $4.32 billion, compared with $4.31 billion to $4.35 billion previously. It continues to project adjusted earnings per share of $4.58 to $4.66.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 04, 2026 18:49 ET (22:49 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2641619832"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641619832\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641619832?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 06:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641619832","market":"sh","top_or_hot":-1,"title":"CooperCompanies Stock Rises After 2Q Rev Increases, Topping Analyst Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CooperCompanies gained after the company logged higher sales in its latest quarter that topped Wall Street's estimates. \n</p>\n<p>\n  The stock rose 4.8% to $65.01 in after-hours trading on Thursday. Through market close, shares were down 24% year to date. \n</p>\n<p>\n  The medical device company said revenue rose 8% to $1.08 billion in the second quarter, topping analyst estimates of $1.05 billion, according to FactSet. \n</p>\n<p>\n  Chief Executive Al White said the results were supported by new product launches and favorable demand drivers. \n</p>\n<p>\n  CooperCompanies also posted a second-quarter loss of $77.9 million, or 40 cents a share, compared with a profit of $87.7 million, or 44 cents a share, a year earlier. The loss was driven by a litigation-related charge to resolve outstanding claims associated with a 2023 voluntary product recall at CooperSurgical, the company said. \n</p>\n<p>\n  Adjusted earnings per share were $1.21, above FactSet analyst estimates of $1.10 a share. \n</p>\n<p>\n  For the full year, the company now expects revenue of $4.29 billion to $4.32 billion, compared with $4.31 billion to $4.35 billion previously. It continues to project adjusted earnings per share of $4.58 to $4.66. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 04, 2026 18:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CooperCompanies Stock Rises After 2Q Rev Increases, Topping Analyst Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCooperCompanies Stock Rises After 2Q Rev Increases, Topping Analyst Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-05 06:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of CooperCompanies gained after the company logged higher sales in its latest quarter that topped Wall Street's estimates. \n</p>\n<p>\n  The stock rose 4.8% to $65.01 in after-hours trading on Thursday. Through market close, shares were down 24% year to date. \n</p>\n<p>\n  The medical device company said revenue rose 8% to $1.08 billion in the second quarter, topping analyst estimates of $1.05 billion, according to FactSet. \n</p>\n<p>\n  Chief Executive Al White said the results were supported by new product launches and favorable demand drivers. \n</p>\n<p>\n  CooperCompanies also posted a second-quarter loss of $77.9 million, or 40 cents a share, compared with a profit of $87.7 million, or 44 cents a share, a year earlier. The loss was driven by a litigation-related charge to resolve outstanding claims associated with a 2023 voluntary product recall at CooperSurgical, the company said. \n</p>\n<p>\n  Adjusted earnings per share were $1.21, above FactSet analyst estimates of $1.10 a share. \n</p>\n<p>\n  For the full year, the company now expects revenue of $4.29 billion to $4.32 billion, compared with $4.31 billion to $4.35 billion previously. It continues to project adjusted earnings per share of $4.58 to $4.66. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 04, 2026 18:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COO","symbol_name":"库珀医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2641619832","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641619832","pubTimestamp":1780613340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CooperCompanies gained after the company logged higher sales in its latest quarter that topped Wall Street's estimates.The stock rose 4.8% to $65.01 in after-hours trading on Thursday. Through market close, shares were down 24% year to date.The medical device company said revenue rose 8% to $1.08 billion in the second quarter, topping analyst estimates of $1.05 billion, according to FactSet.Chief Executive Al White said the results were supported by new product launches and favorable demand drivers.CooperCompanies also posted a second-quarter loss of $77.9 million, or 40 cents a share, compared with a profit of $87.7 million, or 44 cents a share, a year earlier. The loss was driven by a litigation-related charge to resolve outstanding claims associated with a 2023 voluntary product recall at CooperSurgical, the company said.Adjusted earnings per share were $1.21, above FactSet analyst estimates of $1.10 a share.For the full year, the company now expects revenue of $4.29 billi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COO":"库珀医疗","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","BK4198":"医疗保健用品","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1992135399.USD":"Allianz Global Intelligent Cities AT Acc USD","LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","LU2272731782.SGD":"Allianz Global Intelligent Cities AM Dis H2-SGD"},"translate_title":"CooperCompanies股价在第二季度营业额增加后上涨，超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COO":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of CooperCompanies gained after the company logged higher sales in its latest quarter that topped Wall Street's estimates. \n\n\n  The stock rose 4.8% to $65.01 in after-hours trading on Thursday. Through market close, shares were down 24% year to date. \n\n\n  The medical device company said revenue rose 8% to $1.08 billion in the second quarter, topping analyst estimates of $1.05 billion, according to FactSet. \n\n\n  Chief Executive Al White said the results were supported by new product launches and favorable demand drivers. \n\n\n  CooperCompanies also posted a second-quarter loss of $77.9 million, or 40 cents a share, compared with a profit of $87.7 million, or 44 cents a share, a year earlier. The loss was driven by a litigation-related charge to resolve outstanding claims associated with a 2023 voluntary product recall at CooperSurgical, the company said. \n\n\n  Adjusted earnings per share were $1.21, above FactSet analyst estimates of $1.10 a share. \n\n\n  For the full year, the company now expects revenue of $4.29 billion to $4.32 billion, compared with $4.31 billion to $4.35 billion previously. It continues to project adjusted earnings per share of $4.58 to $4.66. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 04, 2026 18:49 ET (22:49 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}